Related Experiment Video
Updated: May 21, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Rat CYP2D2, not 2D1, is functionally conserved with human CYP2D6 in endogenous morphine formation
Nadja Grobe1, Toni M Kutchan, Meinhart H Zenk
1Donald Danforth Plant Science Center, 975 North Warson Road, St. Louis, MO 63132, USA.
FEBS Letters
|May 30, 2012
Summary
Rat CYP2D2, not CYP2D1, metabolizes morphine precursors like thebaine and codeine, challenging previous assumptions about CYP2D6 enzyme activity. This finding necessitates re-evaluating other substrates linked to CYP2D1.
Area of Science:
- Biochemistry
- Pharmacology
- Drug Metabolism
Background:
- The cytochrome P450 2D6 (CYP2D6) enzyme is crucial for metabolizing many drugs.
- CYP2D1 has been widely considered the primary rat ortholog of human CYP2D6.
- This assumption has guided numerous preclinical studies using rat models.
Purpose of the Study:
- To re-evaluate the functional similarity between rat CYP2D1 and human CYP2D6.
- To investigate the metabolic activity of rat CYP2D1 and CYP2D2 using known CYP2D6 substrates.
- To clarify the correct ortholog for CYP2D6 in rat models.
Main Methods:
- Utilized recombinant CYP2D1 and CYP2D2 proteins.
- Performed direct enzyme assays with known CYP2D6 substrates: thebaine, codeine, and (R)-reticuline.
- Analyzed reaction products using mass spectrometry.
- Determined kinetic parameters using Michaelis-Menten analysis.
Main Results:
- Rat CYP2D2, not CYP2D1, catalyzed the 3-O-demethylation of thebaine and codeine.
- CYP2D2 metabolized (R)-reticuline into four products via intramolecular phenol-coupling, a reaction CYP2D1 could not perform.
- CYP2D2 exhibited high catalytic efficiency for these reactions.
- CYP2D1 showed no significant activity towards the tested substrates.
Conclusions:
- Rat CYP2D2 is functionally analogous to human CYP2D6, not CYP2D1.
- Previous research relying on CYP2D1 as a CYP2D6 model may require reinterpretation.
- Further investigation into other substrates commonly associated with CYP2D1 is warranted.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...